Rosewell Shaw et al. (2017) found that mono treatment for head and neck squamous cell carcinoma using HER2-targeted CAR-T-cells led to mice survival for 25 days, however, when this was combined with an engineered oncolytic adenovirus, mice survival was significantly improved to over 100 days. The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.